<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504475</url>
  </required_header>
  <id_info>
    <org_study_id>WS-CP-06-201709-01</org_study_id>
    <nct_id>NCT03504475</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers</brief_title>
  <official_title>An Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study of Paroxetine Hydrochloride 20 mg Tablets and Paxil® Under Fasting Conditions and Under Fed Conditions in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Winsunny Pharmceutical Co.,Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of paroxetine&#xD;
      hydrochloride 20 mg tablets (test) and Paxil® (reference) administered as 20 mg tablet under&#xD;
      fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is an Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence&#xD;
      Study with a washout period of 14 days. During each session, the subjects will be&#xD;
      administered a single dose of 20 mg Paroxetine (one Paroxetine Hydrochloride Tablet 20mg or&#xD;
      one Paxil® Tablet 20 mg) under Fasting and Fed conditions. Venous blood samples will be&#xD;
      collected at pre-dose (0 h), and up to 96 h post dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Actual">June 16, 2018</completion_date>
  <primary_completion_date type="Actual">April 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Blood samples collected over 96 hour period</time_frame>
    <description>Maximum Observed Concentration (of Paroxetine in Plasma)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-∞)</measure>
    <time_frame>Blood samples collected over 96 hour period</time_frame>
    <description>Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>Blood samples collected over 96 hour period</time_frame>
    <description>Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Obsessive-Compulsive Disorder</condition>
  <condition>Panic Disorder</condition>
  <condition>Social Anxiety Disorder</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Paroxetine Hydrochloride Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paxil®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine Hydrochloride Tablet 20 mg</intervention_name>
    <description>A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.</description>
    <arm_group_label>Paroxetine Hydrochloride Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paxil® 20 mg</intervention_name>
    <description>Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.</description>
    <arm_group_label>Paxil®</arm_group_label>
    <other_name>Paroxetine Hydrochloride Tablet 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects are fully informed and voluntarily consent to participate in this study.&#xD;
&#xD;
          2. Healthy adult volunteers of ≥18 years old and ≤ 65 years old, male or female.&#xD;
&#xD;
          3. Body weight ≥ 50.0 kg for male and 45.0 kg for female , and body mass index (BMI)&#xD;
             ranges from 19.0 to 28.0 kg/m2(including).&#xD;
&#xD;
          4. The results of physical examination, vital signs examination, clinical laboratory&#xD;
             examination (blood routine, urine routine, blood biochemistry), 12-lead&#xD;
             electrocardiogram (ECG), chest radiograph were normal or no clinical significant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy or hypersensitivity to paroxetine or components in the formulation, or have&#xD;
             clear history of drug allergies, or have been diagnosed with allergic constitution.&#xD;
&#xD;
          2. History of any diseases which could interfere with the clinical safety or the process&#xD;
             in vivo of the drug, such as liver, kidney, cardiovascular, tuberculosis, epilepsy,&#xD;
             asthma, diabetes or glaucoma disease, especially the endocrine disease,&#xD;
             gastrointestinal disease, gastrointestinal surgery, or unresolved gastrointestinal&#xD;
             symptoms (such as diarrhea, vomiting).&#xD;
&#xD;
          3. Present of any unstable or recurrent diseases , or diseases that interfere with the&#xD;
             process in vivo of the drug.&#xD;
&#xD;
          4. History of drug abuse/dependence, drug-taking, or positive urine drug screen at&#xD;
             screening.&#xD;
&#xD;
          5. Significant alcohol abuse within 2 years ( more than two units of alcohol per day,&#xD;
             drink at least 14 units of alcohol per week: 1 unit = 285 mL of beer or 120 mL of&#xD;
             white spirit or 25 mL of spirit or 100 mL of wine) ,or positive alcohol exhalation&#xD;
             test at screening.&#xD;
&#xD;
          6. Smoking within 1 year (more than 5 cigarettes per day), or could not avoid smoking&#xD;
             during the study period started from signing the informed consent forms.&#xD;
&#xD;
          7. Use of any medication changed the liver enzyme activity within the 28 days prior to&#xD;
             the study.&#xD;
&#xD;
          8. Use of any medication within 14 days prior to the study.&#xD;
&#xD;
          9. With special diet (including grapefruit and/or xanthine, etc.) or vigorous exercise,&#xD;
             or other factors that affected the drug absorption/distribution/metabolism/excretion&#xD;
             within 14 days prior to the study.&#xD;
&#xD;
         10. Volunteer in any other clinical drug study within 90 days prior to the study.&#xD;
&#xD;
         11. Blood donation or lost more than 200 mL of blood within 90 days prior to the study.&#xD;
&#xD;
         12. History of needlesickness or hematophobia, or cannot tolerate venipuncture.&#xD;
&#xD;
         13. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)&#xD;
             antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test.&#xD;
&#xD;
         14. Have the family fertility plan, unwilling or unable to take effective contraceptive&#xD;
             methods to prevent pregnancy from 30 days before the study until 6 months after the&#xD;
             end of study.&#xD;
&#xD;
         15. Positive Human chorionic gonadotropin (HCG) results for female, or lactating women.&#xD;
&#xD;
         16. Have special diet, cannot control diet and exercise as requested.&#xD;
&#xD;
         17. Other situations that the researchers considered unsuitable to enroll the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing TongRen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing TongRen Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>December 16, 2018</last_update_submitted>
  <last_update_submitted_qc>December 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Panic Disorder</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

